Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AstroStem in Mild Alzheimer's Disease
NCT04482413Phase 2Unknown
- Sponsor
- NatureCell
- Start
- Feb 2023
- Primary completion
- May 2024
- Modality
- Mesenchymal Stem Cells, Patient-derived iPSCs, Allogeneic iPSCs
01
Overview
Phase 2, randomised, double-blind trial in Alzheimer's disease (AD) comparing AstroStem with Placebo (2 arms). Primary endpoint: Standard Uptake Value Ratio at 52 Weeks. Status: unknown.
02
Drugs
astrostem
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04482413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04482413.